학술논문
Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer.
Document Type
journal article
Author
Rosenberg, Steven A.; Lotze, Michael T.; Yang, James C.; Topalian, Suzanne L.; Chang, Alfred E.; Schwartzentruber, Douglas J.; Aebersold, Paul; Leitman, Susan; Linehan, W. Marston; Seipp, Claudia A.; White, Donald E.; Steinberg, Seth M.; Rosenberg, S A; Lotze, M T; Yang, J C; Topalian, S L; Chang, A E; Schwartzentruber, D J; Aebersold, P; Leitman, S
Source
JNCI: Journal of the National Cancer Institute; 4/21/1993, Vol. 85 Issue 8, p622-632, 11p
Subject
Language
ISSN
00278874
Abstract
Copyright of JNCI: Journal of the National Cancer Institute is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)